Kosan stops KOS-862 Phase II

KOSN discontinued a Phase II (KOS-202) trial of its KOS-862 (Epothilone D) to treat advanced hormone refractory prostate cancer (HRPC) after interim data showed that it missed the primary endpoint of change in prostate-specific antigen (PSA) levels. Results from the trial also showed a higher incidence of adverse events than in a Phase II trial of KOS-862 to treat non-small cell lung cancer (NSCLC). KOSN expects final data from KOS-202 in first half of 2006. ...